Back to School: How biopharma can reboot drug development. Access exclusive analysis here

XL880: Interim Phase IIb data

Interim data from an ongoing Phase IIb trial of XL880 showed that 15 of 19 evaluable patients had decreases in tumor

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE